Justin Ballotta has over 23 years of experience in the medical device industry spanning product design and development, clinical trials, quality, marketing and manufacturing.

Most recently, Justin was the Chief Operating Officer at Cardiva Medical, acquired by Haemonetics in January 2021 for $510MM.  Justin joined Cardiva, a PTV Healthcare Capital portfolio company, in June 2010; he was directly responsible for Product Development, Manufacturing, Supply Chain, Quality, Clinical and Regulatory Affairs and Customer Operations.

While at Cardiva, Justin led the approval of two PMA-track vascular closure devices and completed several multi-center, prospective clinical trials focused on clinical efficacy and economic value. Justin’s PMA and clinical trials efforts at Cardiva led to the first multi-vessel closure system for cardiac ablation procedures and achieved the first labeling for same day discharge for these procedures. In 2018, Justin led the building of a new offshore manufacturing facility that was recipient of the prestigious Shingo Award for manufacturing and operational excellence in 2018.

Prior to Cardiva, Justin spent 12 years at Johnson & Johnson with increasing senior leadership roles ultimately leading to responsibility for new business assessments and strategic marketing for next generation structural heart and drug-eluting stents. While at Johnson & Johnson subsidiary, Cordis Corporation, Justin was the General Manager for the Cardiovascular Technologies (CVT) business unit where he was responsible for global product development and commercialization in both the US and the EU (Netherlands). Preceding this leadership role, Justin spent three years in the Netherlands leading research and development for coronary stent delivery systems and PTCA catheters. In 2000, Justin was a technical leader for the Checkmate System, the first brachytherapy device to utilize gamma radiation for the treatment of in-stent restenosis. 

Justin co-founded Bio-Trainers, LLC; a company that focused on scanning technology of human cadavers for the development of surgical training tools, namely ACL and MCL repair and was funded with NIH grants.

Justin currently serves as a Director on the Board for Kardion, Inc. and as an Observer on the Board of Directors of Distal Motion, Revival portfolio companies.

He holds a B.S. in Biomedical & Mechanical Engineering from the University of Miami, an M.S. in Engineering Management from Florida International University and an MBA from both the Columbia Business School and the Haas School of Business at University of California Berkeley. 

In the News…